Primeira Realização de Implante Transcateter de Valva Tricúspide Via Transjugular com o Sistema Lux-Valve Plus Na América Latina. Um Relato de Caso

Modine,Thomas

DOI: https://doi.org/10.36660/abc.20240201

2024-10-27

Arquivos Brasileiros de Cardiologia

Abstract:Esteves, Vinicius ; Andrade, Pedro Beraldo De ; Kreimer, Sergio ; Esteves, Fernanda Almeida ; Magalhães, Francisco Monteiro De Almeida ; Modine, Thomas ;

cardiac & cardiovascular systems

What problem does this paper attempt to address?

Treatment of degenerated mitral bioprosthesis using inovare alpha rapid deployment balloon-expandable prosthesis-a minimally invasive approach

Ricardo Barros Corso,Marcus Vinicius Nascimento Dos Santos,Glauco Kalil da Silva Pina,João Carlos Ferreira Leal

DOI: https://doi.org/10.1093/icvts/ivae160

2024-10-08

Abstract:This case report describes an 82-year-old woman with severe mitral bioprosthesis stenosis and NYHA II-III heart failure, EuroScore II of 22.54% and STS Score of 13.7%. She received innovative treatment with transatrial mitral valve-in-valve implantation of a rapid deployment balloon-expandable prosthesis via video-assisted right lateral mini-thoracotomy, with myocardial protection through ventricular fibrillation. The patient was discharged and, under cardiology follow-up, achieved NYHA I class with no angina.
First-in-man implantation of the retrievable and repositionable VenusA-Plus valve.

Xian-Bao Liu,Yu-Xin He,Chun-Hui Liu,Li-Han Wang,Feng Gao,Lei Yu,Ai-Qiang Dong,Min-Jian Kong,Ji-Fang Chen,Yong Xu,Qi-Jing Zhou,Min Yan,Jian-An Wang

DOI: https://doi.org/10.5847/wjem.j.1920-8642.2018.01.010

2018-01-01

World Journal of Emergency Medicine

Abstract:BACKGROUND: No retrievable and repositionable second generation transcatheter aortic valve is available in China. Here, we report the first-in-man implantation of the retrievable and repositionable VenusA-Plus valve. METHODS: A 76-year-old patient with symptomatic severe aortic stenosis and high surgical risk (STS 13.8%) was recommended for transcatheter aortic valve replacement (TAVR) by heart valve team. Type 0 bicuspid aortic valve with asymmetric calcification was identified by dual source computed tomography, and the unfavorable anatomies increased the possibility of malposition and paravalvular leakage during TAVR. Therefore, we used the retrievable and repositionable VenusAPlus valve for the patient. RESULTS: Transfemoral TAVR was performed under local anesthesia with sedation, and a 26mm VenusA-Plus valve was successfully implanted. No transvalvular pressure gradient and trace paravalvular leakage were found. CONCLUSION: The successful first-in-man implantation indicates the retrievable and repositionable VenusA-Plus valve is feasible in complicated TAVR cases such as bicuspid aortic valve.
Percutaneous valve implantation in "tricuspid" position after a Fontan-Björk operation

Inês C Mendes,Fernando Maymone-Martins,Rui Anjos

DOI: https://doi.org/10.1111/jocs.12853

Abstract:A 30-year-old female with tricuspid valve atresia, ventricular septal defect, and atrial septal defect had a neonatal modified Blalock Taussig shunt and a Fontan-Björk operation performed at five years of age. She did well initially but progressively developed signs of systemic congestion due to severe homograft stenosis and underwent successful percutaneous implantation of a Melody® pulmonary valve (Medtronic, Minneapolis, MN, USA) in the "tricuspid" position.
Fatores Associados aos Custos do Tratamento no Primeiro Ano após Implantes Iniciais ou Trocas de Geradores de Pulsos de Marca-passos Cardíacos

Costa,Roberto

DOI: https://doi.org/10.36660/abc.20230386

2024-04-26

Arquivos Brasileiros de Cardiologia

Abstract:Alves, Lucas Bassoli De Oliveira ; Silva, Katia Regina ; Barros, Jacson Venancio ; Colugnati, Fernando Antonio Basile ; Martinelli Filho, Martino ; Costa, Roberto ; Figura Central : Fatores Associados aos Custos do Tratamento no Primeiro Ano após Implantes Iniciais ou Trocas de Geradores de Pulsos de Marca-passos Cardíacos

cardiac & cardiovascular systems
Combined transcatheter aortic valve and tricuspid valve‐in‐valve implantation in a patient with a mitral mechanical prosthesis

Maria Rita Lima,João Brito,Manuel Almeida,Rui Campante Teles

DOI: https://doi.org/10.1002/ccd.31057

IF: 2.3

2024-04-21

Catheterization and Cardiovascular Interventions

Abstract:Despite progressively uncommon in Western countries, rheumatic heart disease still portrays a significant global burden. In elderly or high‐surgical risk patients, plurivalvular disease may require a complex percutaneous approach. Transcatheter aortic valve implantation (TAVI) in patients with previous monoleaflet mitral prosthesis is challenging due to interference between the aortic valve and the rigid mitral mechanical prosthesis "ring." Prior cases report the use of CoreValve or Edwards Sapien aortic valves in patients with adequate mitro‐aortic distance. Performing a second major procedure, such as tricuspid valve‐in‐valve (TVIV), sequentially during a single percutaneous intervention, increases treatment complexity. An 83‐year‐old woman with rheumatic heart disease, with previous implantation of a Bjork–Shiley monoleaflet mitral prosthesis, and Carpentier‐Edwards 29 tricuspid bioprosthesis presented with decompensated heart failure due to severe aortic stenosis and tricuspid bioprosthesis stenosis. After HeartTeam discussion, the patient was deemed as inoperable due to a prohibitive surgical risk. As an alternative, a TAVI (Navitor FlexNav) and a transcatheter TVIV replacement (Edwards Sapiens 3 Ultra) were discussed and proposed, with both techniques being performed sequentially in a single procedure. TAVI in a patient with a previous monoleaflet mitral mechanical prosthesis and TVIV may be a feasible approach in inoperable patients with plurivalvular disease.

cardiac & cardiovascular systems
Tricuspid Regurgitation in a Patient with Heart Transplant: Percutaneous Management

Pabla Cataldo,Franco Appiani,Christian Dauvergne,Óscar Cuevas,Manuel Duarte,Camila Hernández,Christian Garrido,Jorge Sandoval

DOI: https://doi.org/10.4067/s0034-98872024000300395

Abstract:Tricuspid regurgitation (TR) is the most frequent valvular complication after heart transplantation with different clinical sequelae. In its most severe form, it can cause right heart failure with a poor long-term prognosis. Its management is complex, both medical, surgical, and percutaneous. The TricValve system, a bicaval system with two self-expanding valves (superior vena cava and inferior vena cava), dedicated to treating symptomatic IT refractory to medical therapy, is safe and effective in improving quality of life. We present the first heart transplant patient with severe symptomatic TR who underwent successful bicaval valve (TricValve) implantation.
Simultaneous transcatheter dual valve replacement (mitral and tricuspid valves): a case report

Piyush Garg,Nagendra Chouhan,Gagandeep S Wander,Praveen Chandra,Rahul Kashyap

DOI: https://doi.org/10.1093/ehjcr/ytad344

2023-08-01

Abstract:Background: Structural valve dysfunction in bioprosthetic heart valves necessitates redo replacement procedure that are associated with high mortality and morbidity. The transcatheter valve-in-valve (VIV) approach has emerged as a preferred option for patients requiring redo procedures due to structural valve degeneration. We report from India the first case of the simultaneous transcatheter dual VIV implantation (mitral valve and tricuspid valves) in a high-surgical-risk patient. Case summary: A 57-year-old female was presented with a history of rheumatic heart disease, post-mitral valve as well as tricuspid valve replacement (perimount 33 mm) 11 years back. Bioprosthetic heart valve was chosen probably due to limited life expectancy and compliance issues with monitoring of international normalised ratio (INR). She now presented with progressive dyspnoea, oedema, and palpitations (New York Heart Association Class III) for the last 6 months. The patient was scheduled for transcatheter dual valve replacement simultaneously. The procedure was successful with a favourable outcome, short hospital stays, and early recovery. Discussion: This is the first case of simultaneous transcatheter dual valve replacement reported from India, which is fluoroscopically guided and supported by TEE. It is a valuable and considerable option for patients with failing bioprosthesis valves who are at increased peri-operative risk.
Transfemoral and transseptal valve-in-valve implantation into a failing mitral xenograft with a balloon-expandable biological valve

Ulrich Schaefer,Christian Frerker,Dimitry Schewel,Thomas Thielsen,Felix Meincke,Felix Kreidel,Karl-Heinz Kuck

DOI: https://doi.org/10.1016/j.athoracsur.2012.04.123

Abstract:Valve-in-valve implantation for degenerated surgical bioprosthetic valves is becoming an increasingly accepted approach in selected high-risk patients. In the past, valve-in-valve implantations have been mainly performed in aortic position and only rarely in mitral position. We describe the case of an 81-year-old female patient with severe mitral regurgitation of a degenerated Carpentier-Edwards biological prosthesis treated by transfemoral and transseptal implantation of a SAPIEN-XT valve.
Biomechanical performance of the Bicaval Transcatheter System for the treatment of severe tricuspid regurgitation

Fabrizio Crascì,Stefano Cannata,Giovanni Gentile,Caterina Gandolfo,Salvatore Pasta

DOI: https://doi.org/10.3389/fbioe.2023.1179774

2023-05-18

Abstract:Introduction: Tricuspid regurgitation (TR) is a relatively common valvular disease, which can result from structural abnormalities of any anatomic part of the tricuspid valve. Severe TR is linked to congestive heart failure and hemodynamic impairment, resulting in high mortality when repaired by elective surgery. This study was undertaken to quantify the structural and hemodynamic performance of the novel Transcatheter Bicaval Valves System (TricValve) percutaneously implanted in the superior vena cava (SVC) and inferior vena cava (IVC) of two patients with severe TR and venous congestion. Methods: After developing the SVC and IVC device models, the contact pressure exerted on the vena cava wall was obtained by computational analysis. Both smoothed-particle hydrodynamics (SPH) and computational fluid dynamics were carried out to quantify caval reflux in the right atrium and the pressure field of pre- and post-TricValve scenarios, respectively. Results: Analysis of contact pressure highlighted the main anchoring area of the SVC device occurring near the SVC device belly, while the IVC device exerted pronounced forces in the device's proximal and distal parts. SPH-related flow velocities revealed the absence of caval reflux, and a decrease in time-averaged pressure was observed near the SVC and IVC after TricValve implantation. Discussion: Findings demonstrated the potential of computational tools for enhancing our understanding of the biomechanical performance of structural tricuspid valve interventions and improving the way we design next-generation transcatheter therapies to treat the tricuspid valve with heterotopic caval valve implantation.
Transcatheter Tricuspid Valve-in-valve Implantation for Degenerated Surgical Bioprosthesis.

Jinmiao Chen,Ye Yang,Wenyu Song,Deguang Feng,Yang Yan,Chunsheng Wang,Lai Wei

DOI: https://doi.org/10.1002/ccd.30554

IF: 2.3

2023-01-01

Catheterization and Cardiovascular Interventions

Abstract:BackgroundIsolated redo surgery for degenerated tricuspid bioprosthesis is of very high risk. We aimed to evaluate the safety and efficacy of transcatheter valve-in-valve (TVIV) implantation using a novel balloon expandable Renato valve. MethodsA prospective multicenter study was conducted to enroll patients with degenerated tricuspid bioprostheses. A total of 12 patients underwent TVIV implantation using the Renato valve system via transfemoral, transjugular, or transatrial approaches at three institutions from May 2021 to October 2021. All-cause mortality and hemodynamic performance were evaluated up to 6 months after procedure. ResultsThe median age was 68.2 years, and 75.0% were female. Six patients had a history of rheumatic left-sided valve surgery and late tricuspid valve replacement. The median preoperative Society of Thoracic Surgeons score was 9.9%. The procedures were successful in all cases. Tricuspid regurgitation and paravalvular leak were none or mild in all patients. The median transvalvular gradient decreased from 7.8 mmHg preoperatively to 4.5 mmHg at 6 months after TVIV, respectively. No death occurred and all patients recovered to New York Heart Association functional class I or II during a 6-month follow-up. ConclusionsTVIV implantation with the Renato valve was a safe and effective treatment for degenerated bioprostheses in high-risk patients.
Computed tomography imaging in preprocedural planning of transcatheter valvular heart interventions

Vanessa Lopes,Pedro Carvalho Almeida,Nádia Moreira,Luís Amaral Ferreira,Rogério Teixeira,Paulo Donato,Lino Gonçalves

DOI: https://doi.org/10.1007/s10554-024-03140-9

2024-05-24

The International Journal of Cardiovascular Imaging

Abstract:Cardiac Computed Tomography (CCT) has become a reliable imaging modality in cardiology providing robust information on the morphology and structure of the heart with high temporal and isotropic spatial resolution. For the past decade, there has been a paradigm shift in the management of valvular heart disease since previously unfavorable candidates for surgery are now provided with less-invasive interventions. Transcatheter heart valve interventions provide a real alternative to medical and surgical management and are often the only treatment option for valvular heart disease patients. Successful transcatheter valve interventions rely on comprehensive multimodality imaging assessment. CCT is the mainstay imaging technique for preprocedural planning of these interventions. CCT is critical in guiding patient selection, choice of procedural access, device selection, procedural guidance, as well as allowing postprocedural follow-up of complications. This article aims to review the current evidence of the role of CCT in the preprocedural planning of patients undergoing transcatheter valvular interventions.

radiology, nuclear medicine & medical imaging,cardiac & cardiovascular systems
First in human experience of a new self-expandable percutaneous pulmonary valve implantation using knitted nitinol-wire and tri-leaflet porcine pericardial valve in the native right ventricular outflow tract

Gi Beom Kim,Bo Sang Kwon,Hong Gook Lim

DOI: https://doi.org/10.1002/ccd.26910

Abstract:Balloon-expandable percutaneous pulmonary valve systems using the Melody and Edwards SAPIEN transcatheter heart valves have been increasingly used instead of surgically implantable pulmonary valves. However, limited patients with right ventricular outflow tract (RVOT) lesions are suitable candidates for percutaneous pulmonary valve implantation (PPVI) using these systems after surgical correction of tetralogy of Fallot. Therefore, larger self-expandable valved-stents are being developed for native RVOT lesions. We report the first-in-human case of a new self-expandable PPVI in a patient with a native RVOT lesion using a newly made knitted nitinol-wire stent mounted with a tri-leaflet porcine pericardial valve developed in South Korea. © 2017 Wiley Periodicals, Inc.
First-in-Man Simultaneous Aortic and Mitral Valve Transcatheter Implantation Using Patient-Customized Prostheses

Hendrik Ruge,Erion Xhepa,Michael Joner,Christian König,Thomas Ried,Emin Imeri,Ulf Herold,Markus Krane,Ruediger Lange,Magdalena Erlebach

DOI: https://doi.org/10.1016/j.jaccas.2021.01.032

2021-04-21

Abstract:Valve disease in the presence of porcelain aorta and severe peripheral artery disease challenge physicians in choosing the appropriate therapy. We used a total transcatheter approach, simultaneously implanting a dedicated mitral and aortic valve prosthesis treating a patient with mitral and aortic valve disease at an extremely high surgical risk. (Level of Difficulty: Advanced.).
Transcatheter Tricuspid Valve Replacement With Novel Self-Expanding Valve: Secure Fixation in Insecure Anatomy

David I Blusztein,Rebecca T Hahn,Carlos Godoy Rivas,Isaac George,Susheel K Kodali

DOI: https://doi.org/10.1016/j.jaccas.2023.101773

2023-04-19

Abstract:Current transcatheter tricuspid therapies vary by design with different mechanisms of fixation, anchoring, and therapy. This is the first published report of transfemoral tricuspid valve replacement with the Intrepid device, a valve designed to anchor from annular perimeter oversizing, to treat torrential tricuspid regurgitation from leaflet impingement secondary to a ventricular septal defect occluder. (Level of Difficulty: Advanced.).
Emergency transapical mitral valve-in-valve implantation for bioprosthesis failure: transapical implantation of an Edwards Sapien-XT in a dysfunctional mitral bioprosthesis in a critical patient

Marco Zanobini,Sabrina Manganiello,Giorgia Bonalumi,Raoul Biondi,Marco Russo,Massimo Mapelli,Francesco Alamanni,Matteo Saccocci

DOI: https://doi.org/10.1186/s13019-017-0680-7

2017-12-13

Abstract:Background: Valve-in-Valve (VIV) Transcatheter Aortic Valve Replacement (TAVR) is now the treatment of choice in high-surgical-risk patients with failing aortic bioprosthesis. Although less performed, VIV-Transcatheter Mitral Valve Replacement (TMVR) is a valid treatment option for selected high-risk patients with degenerated mitral bioprostheses. Several cases of elective ViV- TAVR and -TMVR have been reported but only few were performed in critical hemodynamic conditions. Case presentation: We report the case of a patient underwent balloon-expandable transapical mitral valve-in-valve implantation in an emergency setting due to a severe stenosis of a bioprosthesis in mitral position. The procedure was successfully performed, with no residual mitral regurgitation or paravalvular leaks, and uneventful. Conclusion: Transcatheter transapical mitral valve-in-valve implantation could represent a feasible and effective strategy even in critical setting.
Hemodynamics of transcatheter tricuspid valve replacement with Lux-Valve

Wang Wei,Li Ning,Ning Xiaoping,Xu Zhiyun,Li Bailing,Cai Chengliang,Yang Fan,Zhou Guangwei,Bai Yifan,Han Lin,Qiao Fan,Lu Fanglin

DOI: https://doi.org/10.3389/fcvm.2022.1007888

IF: 3.6

2022-10-15

Frontiers in Cardiovascular Medicine

Abstract:Objective: Transcatheter tricuspid valve intervention (TTVI) has emerged as an alternative treatment option for high-risk and inoperable patients with symptomatic tricuspid regurgitation (TR). However, scarce data in hemodynamic profiles were available on TTVI. In this paper, we attempt to report the hemodynamic profiles of LuX-Valve. Methods: 30 patients from July 2020 to July 2021 were enrolled in this study. The patient was diagnosed with severe symptomatic TR. The clinical, invasive hemodynamic, and echocardiographic data were collected. Results: The surgical success rate was 100%. The cardiac index and stroke volume increased sharply from 2.42(2.27, 2.85) and 47.8(43.6, 62.0) to 3.04 ± 0.63 and 57.2 ± 14.7, respectively. With the elimination of TR and the increase of forward blood flow of the tricuspid valve, the extravascular lung water [798.0 (673.0, 1147.0) vs. 850.3 ± 376.1, P < 0.01] increased subsequently. The peak right atrium pressure decreased after Lux-Valve implantation (21.0 ± 6.4 vs. 19.4 ± 6.5, P < 0.05). On the contrary, the nadir right atrium pressure increased [10.0(8.0, 15.0) vs. 12.0(10.0, 17.0), P < 0.01]. Notably, the right atrium pressure difference dropped sharply from 9.0(5.0, 13.0) to 5.0(4.0, 8.0) after Lux-Valve implantation. There was no significant change in the pulmonary artery pressure. The right atrium volume decreased from 128(83, 188) to 91(67, 167) mL at 1 month and 107(66,157) mL at 6 months. With the remolding of the right heart chamber, the tricuspid annulus diameter shrank significantly from 42.5 ± 5.6 to 36.6 ± 6.3 mm at 1 month and 36.0 (33.0, 38.0) at 6 months. Conclusion: Invasive right atrium pressure may act as a potential candidate for TR evaluation and procedural guidance. Elimination of TR by LuX-Valve implantation improves the cardiac output and right atrium pressure and has no significant effect on the pulmonary artery pressure even with the increment of forward blood flow, suggesting the hemodynamic superiority of transcatheter tricuspid valve replacement but needs further study.

cardiac & cardiovascular systems
Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures?

Kyriakos Dimitriadis,Nikolaos Pyrpyris,Konstantinos Aznaouridis,Panagiotis Iliakis,Aggeliki Valatsou,Panagiotis Tsioufis,Eirini Beneki,Emmanouil Mantzouranis,Konstantina Aggeli,Eleftherios Tsiamis,Konstantinos Tsioufis

DOI: https://doi.org/10.3390/life13061417

2023-06-21

Life

Abstract:Tricuspid regurgitation (TR) is a common valvular pathology, estimated to affect 1.6 million people in the United States alone. Even though guidelines recommend either medical therapy or surgical treatment for TR, the misconception of TR as a benign disease along with the high mortality rates of surgical intervention led to undertreating this disease and commonly describing it as a "forgotten" valve. Recently, the development of transcatheter interventions for TR show promising potential for use in the clinical setting. There are currently few approved and numerous tested percutaneously delivered devices, which can be categorized, based on their mechanism of action, to either valve repair or valve replacement procedures. Both procedures were tested in clinical trials and show an echocardiographic reduction in TR sustained for at least 1 year after the procedure, as well as symptom relief and functional improvement of the patients. Device selection should be personalized, taking into consideration the anatomy of each valve and the available options at each heart center. Moreover, appropriate patient selection and timing of the procedure are also crucial for the success of the procedure. In this review, we analyze the clinical trials available for all devices currently approved or tested, aiming to provide a comprehensive summary of the most recent evidence in the field of transcatheter TR interventions.

biology
First Case of the Treatment of Massive Tricuspid Regurgitation With the CroíValve DUO Coaptation Valve in a Patient With a Right Ventricular Pacemaker Lead

Ewa Peszek-Przybyła,Marek Jędrzejek,Grzegorz Smolka,Martin J Quinn,Piotr Pysz,Wojtek Wojakowski

DOI: https://doi.org/10.1016/j.shj.2024.100329

2024-06-25

Abstract:Background: Tricuspid regurgitation (TR) is a common valvular disorder with limited treatment options. It occurs when tricuspid leaflet closure is prevented by dilation of the right heart or in patients with cardiac implantable rhythm devices when the transvalvular lead impedes proper closure of the valve. The management of these patients can be complicated. The removal of the lead often does not improve the TR, and surgical repair is usually not possible because of comorbidities. A number of percutaneous TR repair and replacement devices have been developed; however, the presence of the right ventricular lead can prevent the delivery of these devices, or the device may displace the pacemaker lead. We report the first implant of the CroíValve DUO Transcatheter Tricuspid Coaptation Valve System (Dublin, Ireland) in a patient with massive TR and a right ventricular lead. Methods: The patient was not a fit for surgical treatment and underwent transcatheter treatment following compassionate use approval. The procedure was performed under general anesthetic with echo and X-ray guidance. The device was delivered through the right internal jugular vein. Results: The device was implanted successfully, and the TR was reduced from massive to mild at 90-day follow-up. The patient's quality of life improved significantly with an improvement in 6-minute walk test (382 m at baseline to 467 m at follow-up), the New York Heart Association classification (III at baseline to I at follow-up), and the Kansas City Cardiomyopathy Questionnaire (baseline score 43 increased to 60). The efficacy and clinical improvement have been stable over the past 90 days of follow-up, and the patient has not suffered any adverse events. Conclusions: This is the first implantation of the CroíValve DUO Coaptation Valve System in a patient with a pacemaker lead. In these patients, this device may offer advantages over other current transcatheter approaches.
New Self-Expanding Transcatheter Valve for Off-Pump Transatrial Mitral Valve-In-Ring Implantation

Liang Ma,Zipu Yu,Christoph Huber,Chengchen Li,Linfeng Qian,Jianjie Jiang,Yu Zou

DOI: https://doi.org/10.1159/000433595

IF: 1.9

2015-01-01

Cardiology

Abstract:Objectives: To validate a self-expanding transcatheter valve for off-pump transatrial mitral valve-in-ring (VIR) implantation via a left thoracotomy. Methods: Mitral valve annuloplasty was performed via sternotomy during cardiopulmonary bypass on 9 pigs. After successful weaning from extracorporal circulation, the custom-made, self-expanding transcatheter VIR device was deployed under fluoroscopic guidance within the annuloplasty ring via a left thoracotomy. Hemodynamic data before and after the implantation were recorded. Mitral annulus diameter and valve area were measured by echocardiography. Transvalvular and left-ventricular outflow-tract pressure gradient were measured invasively. Results: Eight successful implantations were performed. Implantation failed in 1 pig because of difficulty with technical delivery of the sheath. Mean transatrial procedure time was 12.6 ± 1.7 min. Hemodynamic status during transatrial implantation was stable, and differences were not statistically significant. Mean mitral annulus diameter and mean mitral orifice area were 2.32 ± 0.2 and 3.84 ± 0.55 cm2, respectively. Mild regurgitation was detected in 7 animals and moderate regurgitation in 1. Mean gradients were 6.1 ± 5.0 mm Hg across the device. Postmortem examination confirmed adequate positioning of devices within the annuloplasty ring. Conclusions: This custom-made transcatheter device allows for safe and reproducible off-pump transatrial mitral VIR implantations. Transatrial access is a promising route to facilitate VIR implantations. Our custom-made stent-valve may be suitable for VIR procedures.
Transcatheter tricuspid valve replacement for functional tricuspid regurgitation after left‐sided valve surgery: A single‐center experience

Yiwei Wang,Mengen Zhai,Yu Mao,Tingting Yang,Guangyu Zhu,Yang Liu,Jian Yang

DOI: https://doi.org/10.1002/ccd.30972

IF: 2.3

2024-02-16

Catheterization and Cardiovascular Interventions

Abstract:Background Functional tricuspid regurgitation (FTR) following left‐sided valve surgery (LSVS) is of clinical significance due to its high recurrence and mortality rates. Transcatheter therapy presents a potential solution to address this issue. Aims The study aimed to assess the safety and efficacy of transcatheter tricuspid valve replacement using the Lux‐Valve system in a single center for patients with FTR after LSVS. Methods From June 2020 to April 2023, 20 patients with symptomatic severe FTR after LSVS were referred to our center. A multidisciplinary cardiac team evaluated these patients for suitability for transcatheter tricuspid valve replacement with Lux‐Valve systems. Primary efficacy and safety endpoints were immediate postoperative tricuspid regurgitation severity ≤ moderate and major adverse events during follow‐up. Results Twenty patients (average age 65.7 ± 7.4 years; 65.0% women) successfully underwent Lux‐Valve system implantation after LSVS. All patients achieved ≤ moderate tricuspid regurgitation immediately after the procedure. Only one patient (5.0%) experienced a procedure‐related major adverse event, leading to in‐hospital mortality due to pulmonary infection. At the 6‐month follow‐up, 17 patients (89.5%) improved to New York Heart Association functional class I to II (p

cardiac & cardiovascular systems

Primeira Realização de Implante Transcateter de Valva Tricúspide Via Transjugular com o Sistema Lux-Valve Plus Na América Latina. Um Relato de Caso

Treatment of degenerated mitral bioprosthesis using inovare alpha rapid deployment balloon-expandable prosthesis-a minimally invasive approach

First-in-man implantation of the retrievable and repositionable VenusA-Plus valve.

Percutaneous valve implantation in "tricuspid" position after a Fontan-Björk operation

Fatores Associados aos Custos do Tratamento no Primeiro Ano após Implantes Iniciais ou Trocas de Geradores de Pulsos de Marca-passos Cardíacos

Combined transcatheter aortic valve and tricuspid valve‐in‐valve implantation in a patient with a mitral mechanical prosthesis

Tricuspid Regurgitation in a Patient with Heart Transplant: Percutaneous Management

Simultaneous transcatheter dual valve replacement (mitral and tricuspid valves): a case report

Transfemoral and transseptal valve-in-valve implantation into a failing mitral xenograft with a balloon-expandable biological valve

Biomechanical performance of the Bicaval Transcatheter System for the treatment of severe tricuspid regurgitation

Transcatheter Tricuspid Valve-in-valve Implantation for Degenerated Surgical Bioprosthesis.

Computed tomography imaging in preprocedural planning of transcatheter valvular heart interventions

First in human experience of a new self-expandable percutaneous pulmonary valve implantation using knitted nitinol-wire and tri-leaflet porcine pericardial valve in the native right ventricular outflow tract

First-in-Man Simultaneous Aortic and Mitral Valve Transcatheter Implantation Using Patient-Customized Prostheses

Transcatheter Tricuspid Valve Replacement With Novel Self-Expanding Valve: Secure Fixation in Insecure Anatomy

Emergency transapical mitral valve-in-valve implantation for bioprosthesis failure: transapical implantation of an Edwards Sapien-XT in a dysfunctional mitral bioprosthesis in a critical patient

Hemodynamics of transcatheter tricuspid valve replacement with Lux-Valve

Transcatheter Tricuspid Valve Interventions: A Triumph for Transcatheter Procedures?

First Case of the Treatment of Massive Tricuspid Regurgitation With the CroíValve DUO Coaptation Valve in a Patient With a Right Ventricular Pacemaker Lead

New Self-Expanding Transcatheter Valve for Off-Pump Transatrial Mitral Valve-In-Ring Implantation

Transcatheter tricuspid valve replacement for functional tricuspid regurgitation after left‐sided valve surgery: A single‐center experience